[go: up one dir, main page]

WO2011089395A1 - Gomme à mâcher antiseptique - Google Patents

Gomme à mâcher antiseptique Download PDF

Info

Publication number
WO2011089395A1
WO2011089395A1 PCT/GB2011/000078 GB2011000078W WO2011089395A1 WO 2011089395 A1 WO2011089395 A1 WO 2011089395A1 GB 2011000078 W GB2011000078 W GB 2011000078W WO 2011089395 A1 WO2011089395 A1 WO 2011089395A1
Authority
WO
WIPO (PCT)
Prior art keywords
chewing gum
gum composition
dcba
amc
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2011/000078
Other languages
English (en)
Inventor
Christopher Gowland
Robert Hardy
Lai Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aesica Pharmaceuticals Ltd
Original Assignee
Aesica Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aesica Pharmaceuticals Ltd filed Critical Aesica Pharmaceuticals Ltd
Priority to GB1212870.8A priority Critical patent/GB2510314A/en
Publication of WO2011089395A1 publication Critical patent/WO2011089395A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols

Definitions

  • the present invention relates to a novel chewing gum composition comprising one or more antiseptic agents, to methods of their preparation and to methods of treatment of oral bacterial and fungal infections.
  • the invention relates to chewing gum compositions comprising 2,4- dichlorobenzyl alcohol and/or amyl-m-cresol.
  • DCBA 2,4-Dichlorobenzyl alcohol
  • the other major active ingredient in Strepsils® is amyl-m-cresol (AMC).
  • UK Patent application number 865672 describes various compositions of DCBA in the form of mouth washes, toothpastes, pastilles, lozenges and boiled sweets for medication of the throat, ointments, jellies and lotions and powders for the treatment of the skin.
  • UK '672 also describes that other substances which possess bacteriostatic and/or fungistatic properties may be included in the compositions, such as, hexachlorophene and amyl-m-cresol.
  • UK Patent Application No. GB 2453770 discloses an oral composition in the form of lozenges comprising a cooling agent, e.g. xylitol, sorbitol, mannitol or erythritol, and one or more active agents.
  • a cooling agent e.g. xylitol, sorbitol, mannitol or erythritol, and one or more active agents.
  • WO 2005/067906 discloses acidulated compositions for the treatment of infections caused by severe acute respiratory syndrome (SARS).
  • SARS is a respiratory disease in humans which is caused by the SARS coronavirus (SARS-CoV).
  • SARS-CoV SARS coronavirus
  • chewing gums are increasingly popular, particularly with younger people. So much so, that in 2006 the world wide chewing gum industry had an estimated value of US $1 billion in sales or 1.3 million metric tonnes of gum. Furthermore, the industry is estimated to have grown by more than 7% in the last three years. In addition, in some countries, such as Japan and the USA, chewing gum is preferred over conventional confectionary, such as lozenges.
  • a chewing gum composition comprising a therapeutically effective amount of 2,4-dichlorobenzyl alcohol (DCBA).
  • DCBA 2,4-dichlorobenzyl alcohol
  • AMC amyl-m-cresol
  • DCBA 2,4-dichlorobenzyl alcohol
  • AMC amyl-m-cresol
  • the chewing gum composition may include a therapeutically effective amount of other antiseptic, antibacterial and analgesic therapeutic agents.
  • agents include but shall not be limited to, analgesics, such as flurbiprofen and oxycodone; antiseptics, such as, hexylresorcinol; cetylpyridinium chloride, dequalinium chloride and combined therapies, such as oxyprofen; local anaesthetics, such as, lidocaine, benzocaine and menthol; mucolytic agents, such as, ambroxol hydrochloride; antitussive agents, such as, dextromethorphan hydrobromide; expectorants, such as, guaifenesin; and combinations thereof.
  • the therapeutically effective amount of the active agent e.g. DCBA, AMC, etc, will vary depending upon, inter alia, the nature of the active agent(s) present in the composition, the severity of the infection to be treated, etc.
  • the amount of DCBA present may be, for example, from 0.5 to 2.0mg per gum piece, or from 0.8 to 1.8mg, or from lmg to 1.5mg, e.g. 1.2 mg.
  • the amount of AMC present may be, for example, from 0.1 to lmg per gum piece, or from 0.3 to 0.8mg, or from 0.5mg to 0.7mg, e.g. 0.6mg.
  • the DCBA to AMC ratio will be about from 4:1 to 1.1 or from 3:1 to 1:1, e.g. 2:1.
  • the chewing gum composition will generally include gum base.
  • the composition of gum base may vary, but as will be understood by the person skilled in the art it will generally comprise one or more ingredients capable of providing the viscoelastic properties essential to the "chewability" of the gum.
  • Such gum bases may be selected from the group consisting of; elastomers for providing elasticity, which may comprise a natural latex, such as, couma macrocarpa, loquat, tunu, jelutong, balata, namaquland rubber, almeidana gum, abba rubber and gutta-percha; vegetable gums, such as chicle, spruce gum and mastic gum; synthetic rubbers, such as, copolymers of butadiene and styrene, butyl rubber; synthetic elastomers such as polyisobutylene and polyisoprene, etc.; resins for providing a cohesive body, such as glycerol esters of gums, terpene resin
  • gum base present in quantities sufficient to make a balanced formula which produces a gum which has sufficient flavour but is also processable to allow for processibility, e.g. into desired shapes, etc.
  • the gum base will be present in amounts ranging from about 8 to about 25% w/w of the chewing gum or from about 12 to about 20% w/w for chewing gum produced in the shape of cubes, pillows, blocks, etc.
  • gum base may be from about 18 to about 24% w/w.
  • the formulation may contain additional excipients as required.
  • Typical excipients include, but are not limited to, acidity regulators, opacifiers, colouring agents, stabilising agents, buffering agents, sweeteners, flavourings, preservatives and the like.
  • Some antiseptic agents such as DCBA may have an undesirable taste and therefore a taste masking agent may be included in the chewing gum composition of the invention.
  • a taste masking may include, but shall not be limited to, compounds such as menthol or peppermint oil.
  • the chewing gum composition may comprise a sweetener.
  • the sweetener may be present as a taste masking agent.
  • Such sweeteners may include, but shall not be limited to, sweeteners, such as, aspartame, polyol sweeteners, such as, (crystalline) xylitol, sorbitol (which is also an excellent humectant and texturising agent), mannitol and erythritol.
  • sweeteners examples include, but shall not be limited to, sucrose, lactose, dextrose, maltose, dextrin, dried inverted sugar, fructose, levulose, galactose, corn syrup and their solids, hydrogenated starch hydrolysates, maltitol, sucralose, aspartame, salts of acesulfame potassium, alitame, saccharin and its salts, cyclamic acid and its salts, glycyrrhizin, dihydrochalcones, thaumatin, monellin, and the like, and optionally mixtures thereof.
  • the amount of sweetener present in the chewing gum composition may vary depending upon, inter alia, the nature of the sweetener, but generally it will be present in an amount in the range of about from 1 to 5% w/w or about from 1 to 3% w/w.
  • the chewing gum composition of the invention may also include one or more flavouring agents.
  • Such flavouring agents may comprise essential oils, synthetic flavours, or mixtures thereof including, but not limited to, oils derived from plants and fruits such as citrus oils, including lemon, orange, lime, grapefruit, fruit essences, including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot, banana, blueberry, tutti frutti, etc; mint, peppermint oil, spearmint oil, clove oil, oil of wintergreen, anise, sassafras, sage, eucalyptus, marjoram, cinnamon, methyl salicylate, and the like.
  • natural and artificial flavouring agents may be used independently or combined in an acceptable blend.
  • flavouring agents which may be mentioned include natural and artificial flavouring agents, such flavouring agents may be synthetic flavour oils, flavouring aromatics and/or oils, oleoresins and extracts derived from plants, leaves, flowers, fruits, etc. and combinations thereof.
  • Non-limiting representative flavour oils include bay oil, anise oil, thyme oil, cedar leaf oil, oil of nutmeg, allspice, oil of sage, mace, oil of bitter almonds, cassia oil, and vanilla, and mixtures thereof.
  • flavouring agents include, but are not limited to, acetaldehyde (apple), benzaldehyde (cherry, almond), anisic aldehyde (liquorice, anise), cinnamic aldehyde (cinnamon), citral, i.e., alpha-citral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), ethyl vanillin (vanilla, cream), heliotrope, i.e., piperonal (vanilla, cream), vanillin (vanilla, cream), alpha-amyl cinnamaldehyde (spicy fruity flavours), butyraldehyde (butter, cheese), valeraldehyde (butter, cheese), citronellal (modifies, many types), decanal (citrus fruits), aldehyde C-8 (citrus fruits), aldeh
  • the flavouring agent may be employed in either liquid form or dried form.
  • the amount of flavouring agent employed herein may vary, depending upon, inter alia, the nature of the therapeutically active agent(s), and the flavouring agent(s), the gum base employed, etc.
  • the flavouring agent may generally be present in an amount from about 0.02% to about 5% w/w, or from about 0.1% to about 2% w/w, or from about 0.8% to about 1.8% w/w of the chewing gum composition.
  • the chewing gum composition of the invention may also include one or more colouring agents.
  • Colouring agents may include natural food dyes or artificial colourings, such as brilliant blue (E133), indigotine (E132), Fast green (E143), Allura red (E129) Erythrosine (pink)(E127), tartrazine (E102) and sunset yellow (El 10).
  • Waxes, useful as softening agents include natural and synthetic waxes, hydrogenated vegetable oils, petroleum waxes such as polyurethane waxes, polyethylene waxes, paraffin waxes, microcrystalline waxes, fatty waxes, sorbitan monostearate, tallow, propylene glycol, mixtures thereof, etc which may be incorporated into the gum base.
  • Suitable fillers and/or texturisers may include magnesium carbonate, calcium carbonate, sodium sulphate, ground limestone, silicates, such as magnesium silicate and aluminium silicate, kaolin, clay, aluminium oxide, silicium oxide, talc, titanium oxide, mono-, di- and tri-calcium phosphates, cellulose polymers, and combinations thereof.
  • Suitable fillers and/or texturisers may also include natural organic fibres such as fruit or vegetable fibres, grain, rice, celluloses and combinations thereof.
  • Other useful fillers substances include sorbitol, mannitol, dextrins, maltodextrins, inositol, erythritol, isomalt, lactitol, maltitol, mannitol, xylitol, low- substituted hydroxypropylcellulose, starches or modified starches (e.g. potato starch, maize starch, rice starch, pre-gelatinised starch), polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, agar (e.g.
  • sodium alginate carboxyalkylcellulose, dextrates, gelatine, gummi arabicum, hydroxypropyl cellulose, hydroxypropylmethylcellulose, methylcellulose, microcrystalline cellulose, polyethylene glycol, polyethylene oxide, polysaccharides e.g. dextran, soy polysaccharide, sodium carbonate, and sodium chloride.
  • a unit of the chewing gum composition of the invention may be coated or uncoated.
  • a suitable coating may be a hard coating, a soft coating, a film coating or a sealing coating or any combination of the aforementioned.
  • the coating may comprise in from 10 to 40% w/w, or 15-30% w/w or 20 to 30% w/w of the chewing gum unit.
  • the coating may be a hard coating, including a sugar coating or a sugar-free coating, and combinations thereof. The objects of hard coating are to obtain a sweet, crunchy layer, which is appreciated by the consumer, and to protect the composition for various reasons.
  • the sugar is desirably a crystallisable sugar, such as sucrose or dextrose.
  • Other coating substances which may be mentioned include polyols, e.g. sorbitol, maltitol, mannitol, xylitol, erythritol, lactitol, isomalt and tagatose, maltose, fructose or levulose, xylose, erythrose, lactose, isomaltulose and D-galactose, respectively.
  • polyols in the coating is that they act simultaneously as a sweetener and as a taste-masking agent for the bitter taste of an active therapeutic agent.
  • the chewing gum composition of the invention does not comprise a cooling agent.
  • the chewing gum composition of the present invention may be an acidulated chewing gum or a non-acidulated chewing gum.
  • a non-acidulated chewing gum is preferred.
  • the coating may be a soft coating.
  • a soft coating may comprise one or more a sugar-less sweetening compound and a starch hydrolysate.
  • Suitable film-coating polymers include edible cellulose derivatives such as cellulose ethers including methylcellulose (MC), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose (HPMC).
  • Other useful film- coating agents are acrylic polymers and copolymers, e.g. methylacrylate aminoester copolymer or mixtures of cellulose derivatives and acrylic polymers.
  • Film coating polymers which may be mentioned include cellulose acetate phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, cellulose acetate trimellitate, and HP C.
  • the coating may generally comprise a plurality of layers.
  • chewing gums herein shall also include compositions such as bubble gums and the like.
  • a method of treatment of a patient suffering from an oral or nasal infection which comprises the administration of a therapeutically active amount of 2,4-dichlorobenzyl alcohol (DCBA) in a chewing gum composition.
  • DCBA 2,4-dichlorobenzyl alcohol
  • AMC amyl-m-cresol
  • a method of treatment of a patient suffering from an oral or nasal infection which comprises the administration of a therapeutically active amount of 2,4-dichlorobenzyl alcohol (DCBA) and amyl- m-cresol (AMC) in a chewing gum composition.
  • DCBA 2,4-dichlorobenzyl alcohol
  • AMC amyl- m-cresol
  • the method of treatment according to this aspect of the invention may include the administration of a therapeutically effective amount of other antiseptic, antibacterial and analgesic therapeutic agents as hereinbefore defined incorporated into the chewing gum composition.
  • DCB A 2,4- dichlorobenzyl alcohol
  • AMC amyl-m-cresol
  • DCBA 2,4-dichlorobenzyl alcohol
  • AMC amyl-m-cresol
  • the method of the invention may comprise the incorporation of one or more therapeutically active antiseptic agents as hereinbefore described and optionally include other antiseptic, antibacterial and analgesic therapeutic agents.
  • a chewing gum composition comprising 2,4-dichlorobenzyl alcohol (DCBA) and/or amyl-m-cresol (AMC) as active antiseptic agent said method comprising;
  • DCBA 2,4-dichlorobenzyl alcohol
  • AMC amyl-m-cresol
  • a wax e.g. carnauba wax
  • the chewing gum composition of the present invention does not include gelatin. Therefore, the present invention provides a chewing gum composition as hereinbefore described comprising a therapeutically effective amount of 2,4-dichlorobenzyl alcohol (DCBA) with the proviso that gelatin is substantially absent; and methods associated thereto. The present invention further provides a chewing gum composition as hereinbefore described comprising a therapeutically effective amount of amyl-m- cresol (AMC) with the proviso that gelatin is substantially absent.
  • DCBA 2,4-dichlorobenzyl alcohol
  • AMC amyl-m- cresol
  • the present invention further provides a chewing gum composition as hereinbefore described comprising a therapeutically effective amount of 2,4-dichlorobenzyl alcohol (DCBA) and a therapeutically effective amount amyl-m-cresol (AMC) with the proviso that gelatin is substantially absent. It is also within the scope of the present invention to provide a liquid filled chewing gum which releases amounts of the antiseptic agents as hereinbefore described into the oral cavity.
  • the liquid filled chewing gum may include a solid phase and a liquid phase, the solid phase comprising a gum base matrix including a network of one or more voids or pockets laced throughout the matrix, and the liquid phase comprising the antiseptic agent composition, retained in the one or more voids or pockets, and surrounded by gum base. Upon chewing, the liquid antiseptic agent composition is released into the oral cavity.
  • Uncoated chicle chewing gum pieces (about lg each) are coated with a sucrose solution (80% w/v) in a coating pan. Powdered hydrogenated castor oil is dusted onto the coated chicle pieces and a coating of 2, 4-dichlorobenzyl alcohol in ethanol is applied. Successive applications of the coating are made until approximately 1.2 mg of 2, 4-dichlorobenzyl alcohol have been deposited on each chicle piece. A finishing coating of a sucrose solution is applied containing desired flavourings and colourings. A polishing coat of wax is optionally added.
  • Uncoated chicle chewing gum pieces (about lg each) are coated with a sucrose solution (80% w/v) in a coating pan. Powdered hydrogenated castor oil is dusted onto the coated chicle pieces and a coating of amyl-m-cresol in ethanol is applied. Successive applications of the coating are made until approximately 0.6 mg of amyl- m-cresol has been deposited on each chicle piece. A finishing coating of a sucrose solution is applied containing desired flavourings and colourings, A polishing coat of wax is optionally added.
  • Uncoated chicle chewing gum pieces (about lg each) are coated with a sucrose solution (80% w/v) in a coating pan. Powdered hydrogenated castor oil is dusted onto the coated chicle pieces and a coating of 2, 4-dichlorobenzyl alcohol and amyl-m- cresol in ethanol is applied. Successive applications of the coating are made until approximately 1.2mg of 2, 4-dichlorobenzyl alcohol and 0.6 mg of amyl-m-cresol have been deposited on each chicle piece. A finishing coating of a sucrose solution is applied containing desired flavourings and colourings. A polishing coat of wax is optionally added.
  • a sucrose solution 80% w/v
  • uncoated chewing gum pieces (about 3g each) were rolled into small spheres that were coated with a sucrose solution (80% w/v) in a coating pan.
  • Carnauba wax was applied to the coated gum spheres and a coating of 2, 4- dichlorobenzyl alcohol and amyl-m-cresol in ethanol was applied. Successive applications of the coating were made until approximately 1.2mg of 2, 4- dichlorobenzyl alcohol and 0.6 mg of amyl-m-cresol had been deposited per gram of uncoated chewing gum.
  • a finishing coating of a sucrose solution was applied containing desired flavourings and colourings.
  • the a chewing gum composition of the invention is useful for, inter alia, alleviating, mitigating or preventing sore throat symptoms, including, but, not limited to, pain, dryness and/or inflammation.
  • the effectiveness of the chewing gum composition of the invention is demonstrated by means of clinical trials in which patients suffering from sore throats are administered the chewing gum composition of the invention, such as that described in Examples 1, 2, 3 and 4 or a placebo. After having chewed the gum, the patient is asked to assess the effectiveness of the treatment, referring to parameters such as the relief of the pain associated with the sore throat, the ease of, or improvement in, swallowing and/or reduction in the swelling of the throat. The patients are also examined by a clinician.
  • Subjects are eligible to participate if they are otherwise healthy, have at least moderate symptom severity and report symptoms of 48 hours or less duration. Symptoms are sore throat symptoms, namely, pain, dryness and/or inflammation of the throat. The trial is blinded.
  • Subjects are randomly assigned to receive coated chewing gum pieces (about lg each) or a placebo chewing gum.
  • the subject chews on gum piece every 2 to 3 hours from about 8 a.m. to 6 p.m.
  • Subjects are instructed to avoid any other cold, flu or sore throat treatments whilst participating in the study. 5.3 Study Procedures
  • the study is a randomised, placebo-controlled clinical trial which is optionally blinded or double-blinded.
  • baseline symptom evaluations are made using a symptom severity scale of 0 to 4, corresponding to absent, mild, moderate, moderately severe, and severe.
  • the symptoms rated are overall throat symptom assessment, sore throat, cough; overall nasal symptom assessment, sneezing, runny nose, nasal obstruction; overall sinus symptom assessment, sinus pain, sinus pressure, sinus congestion; headache, muscle pain, and malaise.
  • These symptom assessments are made by the subjects based on their self-perception of symptom type and location. Height and weight are recorded. Subjects are instructed to record their self-perception of symptoms after chewing each gum. The symptoms and severity scale used in these assessments are the same as those used for the baseline evaluation.
  • Subjects also record the occurrence of any adverse effect. Each subject reports their symptom assessment after 24 to 48. Study diaries are returned and reviewed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Confectionery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une composition de gomme à mâcher qui comporte une quantité thérapeutiquement efficace d'alcool 2,4-dichlorobenzylique (DCBA) et/ou d'amyl-m-crésol (AMC). L'invention porte également sur l'alcool 2,4-dichlorobenzylique (DCBA) et/ou sur l'amyl-m-crésol (AMC) qui sont destinés à être utilisés dans la fabrication d'une composition de gomme à mâcher.
PCT/GB2011/000078 2010-01-22 2011-01-21 Gomme à mâcher antiseptique Ceased WO2011089395A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1212870.8A GB2510314A (en) 2010-01-22 2011-01-21 Antiseptic chewing gum

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1001048.6A GB201001048D0 (en) 2010-01-22 2010-01-22 Antiseptic gum
GB1001048.6 2010-01-22

Publications (1)

Publication Number Publication Date
WO2011089395A1 true WO2011089395A1 (fr) 2011-07-28

Family

ID=42045923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/000078 Ceased WO2011089395A1 (fr) 2010-01-22 2011-01-21 Gomme à mâcher antiseptique

Country Status (2)

Country Link
GB (2) GB201001048D0 (fr)
WO (1) WO2011089395A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004395A1 (fr) * 2014-07-02 2016-01-07 Xlear, Inc Compositions pour angine et procédés associés
US10010638B2 (en) 2016-06-14 2018-07-03 S. C. Johnson & Son, Inc. Wax melt with filler
US10342886B2 (en) 2016-01-26 2019-07-09 S.C. Johnson & Son, Inc. Extruded wax melt and method of producing same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB865672A (en) 1957-06-27 1961-04-19 Boots Pure Drug Co Ltd Antiseptic therapeutic compositions comprising 2:4-dichlorobenzyl alcohol
EP0399479A1 (fr) * 1989-05-26 1990-11-28 Gerhard Dr. Gergely Gomme à mâcher pour la désinfection de la bouche et de la gorge ainsi que son procédé de préparation
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
WO2005067906A2 (fr) 2004-01-14 2005-07-28 Reckitt Benckiser Healthcare (Uk) Limited Composition pharmaceutique
EP1693085A1 (fr) * 2005-01-28 2006-08-23 Gumlink A/S Un kit de nettoyage des dents par la mastification d'un ensemble de gomme à mâcher
US20070003663A1 (en) * 2004-08-25 2007-01-04 Cadbury Adams Usa, Llc. Liquid-filled chewing gum composition
WO2008122286A1 (fr) * 2007-04-04 2008-10-16 Gumlink A/S Chewing-gum à noyau fourré pour soin dentaire
GB2453770A (en) 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB865672A (en) 1957-06-27 1961-04-19 Boots Pure Drug Co Ltd Antiseptic therapeutic compositions comprising 2:4-dichlorobenzyl alcohol
EP0399479A1 (fr) * 1989-05-26 1990-11-28 Gerhard Dr. Gergely Gomme à mâcher pour la désinfection de la bouche et de la gorge ainsi que son procédé de préparation
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
WO2005067906A2 (fr) 2004-01-14 2005-07-28 Reckitt Benckiser Healthcare (Uk) Limited Composition pharmaceutique
US20070003663A1 (en) * 2004-08-25 2007-01-04 Cadbury Adams Usa, Llc. Liquid-filled chewing gum composition
EP1693085A1 (fr) * 2005-01-28 2006-08-23 Gumlink A/S Un kit de nettoyage des dents par la mastification d'un ensemble de gomme à mâcher
WO2008122286A1 (fr) * 2007-04-04 2008-10-16 Gumlink A/S Chewing-gum à noyau fourré pour soin dentaire
GB2453770A (en) 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004395A1 (fr) * 2014-07-02 2016-01-07 Xlear, Inc Compositions pour angine et procédés associés
US10342886B2 (en) 2016-01-26 2019-07-09 S.C. Johnson & Son, Inc. Extruded wax melt and method of producing same
US10010638B2 (en) 2016-06-14 2018-07-03 S. C. Johnson & Son, Inc. Wax melt with filler

Also Published As

Publication number Publication date
GB2510314A (en) 2014-08-06
GB201001048D0 (en) 2010-03-10
GB201212870D0 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
CN1997350B (zh) 释放烟草生物碱的口香糖
RU2416977C2 (ru) Кондитерский продукт
US8858919B2 (en) Method of providing fast relief to a user of a nicotine chewing gum
US6949264B1 (en) Nutraceuticals or nutritional supplements and method of making
CN102481257B (zh) 用于控释活性成分的颗粒材料
CN106456560B (zh) 医用口香糖
KR101132377B1 (ko) 압착된 츄잉 껌 정제
JP4875616B2 (ja) 圧縮チューインガムタブレット
US6627234B1 (en) Method of producing active agent coated chewing gum products
JP2022088537A (ja) 新規経口投与製剤
WO2000035298A1 (fr) Chewing-gum contenant des agents medicamenteux actifs
DK2296486T3 (en) Film-coated compressed gum
JP2005531319A (ja) 樹脂調整圧縮成形チューインガム
PL200826B1 (pl) Baza gumy do żucia, niepowlekana i powlekana guma do żucia oraz sposób wytwarzania powlekanej gumy do żucia
WO2011089395A1 (fr) Gomme à mâcher antiseptique
EP3313383B1 (fr) Composition de gomme à mâcher pour utilisation dans le soulagement de la xérostomie induite par traitement radiothérapique
CA2355779C (fr) Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum
JP5414989B2 (ja) 菓子製品
AU2019239514B2 (en) A solid pharmaceutical tablet
RU2305948C2 (ru) Таблетка прессованной жевательной резинки и способ ее производства
RU2355184C2 (ru) Таблетка прессованной жевательной резинки и способ ее получения
RU2347367C1 (ru) Кондитерский продукт
JP2011057701A (ja) ニコチンチューインガム使用者に迅速な緩和をもたらす方法
JP2014158484A (ja) 圧縮チューインガムタブレット

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11704819

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 1212870

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20110121

WWE Wipo information: entry into national phase

Ref document number: 1212870.8

Country of ref document: GB

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11704819

Country of ref document: EP

Kind code of ref document: A1